CGT & Viral Vector Biosafety Testing

HYQURE supports cell & gene therapy and viral-vector programs with integrated biosafety, vector characterization and replication-competent virus testing. Supported pathways include RCL, RCR, RCA and rcAAV testing, AAV- and lentiviral-vector QC, cell-bank characterization, adventitious-agent control, microbial safety, viral clearance/inactivation where relevant, process-residue testing and lot-release support. For AAV, lentiviral and oncolytic-virus programs, HYQURE combines molecular, cell-based and NGS-enabled approaches to assess vector safety and genetic integrity. NGS workflows can support exogenous-virus screening, plasmid verification, vector-genome integrity, insertion/mutation analysis, genetic-stability assessment and investigation of known or unexpected contaminating sequences. The AAV/LV platform supports development-stage needs from R&D and pilot production through preclinical/clinical testing and larger-scale manufacturing. Programs are scoped according to vector type, production system, matrix, development stage and target market, with method suitability, validation support and controlled reporting for sponsor-facing and regulatory-facing packages.